Clinical trials: Uveitis, Posterior
Intermediate Uveitis, Posterior Uveitis
Retisert and Cataract Surgery in Patients With Severe Uveitis
To review chart data at the Duke Eye Center and determined whether a 3-year fluocinolone acetonide sustained drug delivery system (FA) safely suppressed postoperative inflammation when combined with phacoemulsification and…
- Trial name
- NCT00570830
- Testing
- Retisert (fluocinolone acetonide implant)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Uveitis, Posterior, Uveitis, Intermediate
Ozurdex Monotherapy Trial
This study will investigate the efficacy and safety of OZURDEX® (dexamethasone intravitreal implants; DEX, Allergan, Inc. Irvine, CA) as monotherapy for the treatment of non-infectious intermediate-, posterior- or panuveitis.
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- OM (NCT05101928)
- Testing
- Ozurdex 0.7mg Ophthalmic Implant, Prednisone
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Uveitis; Posterior, Disorder
Study Assessing Double-masked Uveitis Treatment
The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.
- Trial name
- SAKURA (NCT01358266)
- Testing
- DE-109 44 ug, DE-109 440 ug, DE-109 880 ug
- Where
- 151 sites in United States, Argentina and 15 more
- Volunteers
- 592 people
- Sponsor
- Santen Inc.
Non-Infectious Uveitis
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye.
- Trial name
- FAI (NCT01694186)
- Testing
- FAI insert
- Where
- 34 sites in United States, Germany and 4 more
- Volunteers
- 129 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Uveitis
38 Week Extension Study to CAIN457C2303
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with…
- Trial name
- SHIELD (NCT01093846)
- Testing
- AIN457
- Where
- 25 sites in United States, Egypt and 12 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Intermediate Uveitis, Posterior Uveitis
Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
In the STOP-UVEITIS study, we propose to evaluate the safety, tolerability, and bioactivity of two doses of Tocilizumab (4mg/kg and 8mg/kg), administered monthly, in patients with non-infectious intermediate, posterior, or…
- Conditions
- Intermediate Uveitis, Posterior Uveitis, Pan-uveitis
- Trial name
- STOP-Uveitis (NCT01717170)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Nebraska
Ocular Behcet's Disease,, Non-Infectious Uveitis
Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease
Objectives: To describe the safety and efficacy of intravitreal flucinolone acetonide implants in the management of patients having refractory ocular Behcet's disease Hypothesis: A descriptive observational study Study design: A…
- Conditions
- Ocular Behcet's Disease,, Non-Infectious Uveitis, Refractory Uveitis
- Trial name
- NCT00720928
- Testing
- flucinolone acetonide
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Asan Medical Center